Clinical Trials
56 trialsNCT05384626 2026-05-27
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT07193511 2026-05-26
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05674825 2026-05-22
MCW I-PREDICT
Medical College of Wisconsin
Phase 1/2 Recruiting
NCT06796907 2026-05-22
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06941272 2026-05-12
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04802759 2026-05-11
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06818643 2026-05-08
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07335497 2026-05-06
ASCEND
Crescent Biopharma, Inc.
Phase 1/2 Recruiting
NCT05394337 2026-05-05
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05898399 2026-05-01
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT07213817 2026-04-30
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07213830 2026-04-30
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
Phase 1/2 Recruiting
NCT03535246 2026-04-24
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03614650 2026-04-24
Immunotherapy Treating GI Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT05875168 2026-04-20
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
NCT05120596 2026-04-13
First in Human Study of T3P-Y058-739 (T3P)
T3 Pharmaceuticals AG
Phase 1/2 Recruiting
NCT07510828 2026-04-06
PRISM-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07276373 2026-04-03
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Phase 1/2 Recruiting
NCT04333706 2026-03-10
EMPOWER
University of Southern California
Phase 1/2 Recruiting
NCT04723810 2026-03-09
TumorGlow Intraoperative Molecular Imaging (IMI)
University of Pennsylvania
Phase 1/2 Recruiting
NCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06014658 2026-03-02
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT06634849 2026-02-10
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Pathios Therapeutics Pty Ltd
Phase 1/2 Recruiting
NCT05039632 2026-02-06
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04145622 2026-01-28
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
NCT06840119 2026-01-28
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Immunocore Ltd
Phase 1/2 Recruiting
NCT07112222 2026-01-26
A Study of LM-350 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07073534 2026-01-22
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT07197827 2025-12-24
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06311851 2025-11-25
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
Phase 1/2 Recruiting
NCT06184035 2025-11-20
Tumorad
Spago Nanomedical AB
Phase 1/2 Recruiting
NCT05118789 2025-10-24
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT05116072 2025-09-25
TPIAT-01
University Hospital, Lille
Phase 1/2 Recruiting
NCT05697406 2025-09-22
HC-MRI
University of Maryland, Baltimore
Phase 1/2 Recruiting
NCT06193902 2025-09-03
AERIAL
Leucid Bio
Phase 1/2 Recruiting
NCT05394103 2025-08-17
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co., Ltd.
Phase 1/2 Recruiting
NCT06154291 2025-06-22
FIPO23
Xenothera SAS
Phase 1/2 Recruiting
NCT05413473 2025-06-15
Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)
AHS Cancer Control Alberta
Phase 1/2 Recruiting
NCT06987500 2025-06-06
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT06650566 2025-05-02
Study of LM-299 in Subjects Advanced Malignant Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06911333 2025-04-04
AD1208
Avelos Therapeutics Inc.
Phase 1/2 Recruiting
NCT05269316 2025-04-01
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05615974 2024-12-19
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT05918445 2024-12-05
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Biotheus Inc.
Phase 1/2 Recruiting
NCT01542879 2024-11-25
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
Stanford University
Phase 1/2 Recruiting
NCT06612632 2024-09-25
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT05176665 2024-08-26
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting